Shares of pharmaceutical giant (NYSE: PFE) have been steadily sliding lower over the past year as revenue and profits from the pandemic's vaccine boom dry up. Today, the stock has seemingly settled in the high $20s, near the lows of the past decade.
It's time to get the word out: The pessimism on Pfizer stock has gone too far.
At first glance, Pfizer looks like a money pit, but the stock is more of a table-pounding bargain. Here are three reasons investors should consider snapping up Pfizer as a long-term investment with market-beating potential.
Source Fool.com